Advertisement

HIPEC for Recurrent Ovarian Cancer: The CHIPOR Trial
Posted: 01/21/2025 | By: Sarah Campen, PharmD

Hyperthermic intraperitoneal chemotherapy (HIPEC) during interval cytoreductive surgery for ovarian cancer has been shown to improve overall survival, but its role in recurrent disease is uncertain. A recent study published in The Lancet compared outcomes in patients treated with or without HIPEC during surgery for recurrent ovarian cancer.

Question 1 of 5

What patient population was included in the Chemotherapy for Recurrent Ovarian Cancer (CHIPOR) trial?

Choose 1

A
Patients with first relapse of ovarian cancer less than 6 months after completing platinum-based chemotherapy
B
Patients with previously untreated ovarian cancer
C
Patients with first relapse of ovarian cancer at least 12 months after completing platinum-based chemotherapy
D
Patients with first relapse of ovarian cancer at least 6 months after completing last platinum-based chemotherapy

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage